In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asterand PLC

www.asterand.com

Latest From Asterand PLC

STOCKWATCH: Name, Platform; Time of death, December 2013

They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.

Cardiovascular Cancer

Stockwatch: Bad debts and outcomes

Despite what a young biotechnology company's bankers will tell them, raising debt ahead of the approval and commercialisation of the company's first product, is rarely a good idea. The rationale, which probably sounds good at the time, goes something like this. Once the revenues start flowing from the soon to be approved product, they will easily cover the interest on the debt and by the time the principal, or the convertible become due, the company will be cash flow positive and would be able to pay-off, refinance or convert the liability into shares.

Dermatology Wound Healing & Tissue Repair

John Stchur leaves Asterand

Asterand's chief financial officer, John Stchur has left the company to be replaced by Alan Fishman as interim CFO. Mr Stchur served at Asterand for nine years, most recently negotiating the successful acquisition of BioSeek, while Mr Fishman has over 30 years' financial experience.

Ono allies with BioSeek for discovery of novel drugs

Japan's Ono Pharmaceutical is tapping into external drug discovery expertise through an agreement with the small US firm BioSeek which will concentrate on bioactive lipids.

Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Pharmagene PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Asterand PLC
  • Senior Management
  • Jack Davis, Interim CEO
    Alan Fishman, CFO
    Tom Mander, VP, Sales & Mktg.
    Dalia Cohen, PhD, CSO
  • Contact Info
  • Asterand PLC
    Phone: (44) 1763 211 600
    2 Orchard Rd.
    Royston, SG8 5HD
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register